Mubadala Acquires Pharmaceutical Company "Kilex Bio"

Mubadala Investment Company, the sovereign investment firm in Abu Dhabi, announced the signing of an agreement to acquire "Kilex Bio," a company specializing in pharmaceuticals that provides advanced generic medicines in emerging markets. This acquisition is part of efforts to enhance and develop the ecosystem for the pharmaceutical industry in the United Arab Emirates, bolstering its global position in the pharmaceutical and biotechnology sector and supporting economic diversification. Since its establishment in November 2020, "Kilex Bio" has acquired manufacturing companies in India, Egypt, Malta, and Morocco, and has successfully marketed a wide range of oral formulations as well as injectables covering various treatment areas, including diabetes, oncology, cardiovascular diseases, and central nervous system disorders.